利索-全球专利检索

  1. 登录
  2. 注册
发明授权
US08664240B2 R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial 有权
R-7-（3-氨基甲基-4-甲氧基亚氨基-3-甲基 - 吡咯烷-1-基）-1-环丙基-6-氟-4-氧代-1,4-二氢 - [1,8]二氮杂萘-3-酮 - 羧酸和L-天冬氨酸盐，其制备方法和包含其的抗微生物剂的药物组合物

R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial
摘要：
Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl) -1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration.
摘要（中）：

本文公开了R-7-（3-氨基甲基-4-甲氧基亚氨基-3-甲基 - 吡咯烷-1-基）-1-环丙基-6-氟-4-氧代-1,4-二氢 - [1,8] 萘啶-3-羧酸和L-天冬氨酸盐，其制备方法和包含其的抗微生物剂的药物组合物。 因为R-7-（3-氨基甲基-4-甲氧基亚氨基-3-甲基 - 吡咯烷-1-基）-1-环丙基-6-氟-4-氧代-1,4-二氢 - [1,8]萘啶 -3-羧酸和L-天冬氨酸盐比常规使用的盐酸盐和其他盐（D-天冬氨酸盐和磷酸盐）更易溶解，毒性更小，作为抗微生物剂的副作用较小，该盐可用于口服和 注射给药。

公开/授权文献
信息查询
Espacenet
0/0